Takhzyro
Takhzyro is the brand name for lanadelumab, a human monoclonal antibody used to prevent attacks in people with hereditary angioedema (HAE). It works by inhibiting plasma kallikrein, which reduces the production of bradykinin, a molecule that increases vascular permeability and contributes to angioedema attacks.
Indication and use: Takhzyro is approved for routine prophylaxis to prevent angioedema attacks in individuals aged
Administration and dosing: The medicine is given by subcutaneous injection. The approved dosing regimens are 300
Efficacy: In phase 3 clinical trials, lanadelumab significantly reduced the frequency of HAE attacks compared with
Safety and precautions: The most common adverse effects reported include injection-site reactions and upper respiratory tract
Regulatory status: Takhzyro has received regulatory approvals for HAE prophylaxis in the United States and other